Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Systemic Right Ventricles: Incrementally Building the Evidence Base.
作者信息
Marshall William H, Daniels Curt J
机构信息
Department of Internal Medicine, Division of Cardiovascular Medicine The Ohio State University Columbus OH.
Nationwide Children's Hospital The Heart Center Columbus OH.
出版信息
J Am Heart Assoc. 2025 Jun 3;14(11):e043096. doi: 10.1161/JAHA.125.043096. Epub 2025 May 29.
Abstract
摘要
相似文献
1
Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Systemic Right Ventricles: Incrementally Building the Evidence Base.钠-葡萄糖协同转运蛋白2抑制剂在系统性右心室患者中的应用：逐步建立证据基础
J Am Heart Assoc. 2025 Jun 3;14(11):e043096. doi: 10.1161/JAHA.125.043096. Epub 2025 May 29.
2
Systolic and diastolic functional reserve of the subpulmonary and systemic right ventricles as assessed by pharmacologic and exercise stress: A systematic review.药物负荷和运动负荷评估下的亚肺和体循环右心室收缩和舒张功能储备：系统评价。
Echocardiography. 2022 Feb;39(2):310-329. doi: 10.1111/echo.15285. Epub 2022 Jan 7.
3
Safety and Efficacy of Dapagliflozin in Patients With Systemic Right Ventricular Dysfunction: DAPA-SRV Trial.达格列净治疗系统性右心室功能障碍患者的安全性和有效性：DAPA-SRV试验
J Am Heart Assoc. 2025 Jun 3;14(11):e040302. doi: 10.1161/JAHA.124.040302. Epub 2025 May 29.
4
The first experience with sodium-glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure.首例钠-葡萄糖共转运蛋白 2 抑制剂治疗系统性右心衰竭。
ESC Heart Fail. 2022 Jun;9(3):2007-2012. doi: 10.1002/ehf2.13871. Epub 2022 Mar 30.
5
Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure : A Systematic Review and Meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂在心力衰竭患者中的应用：系统评价和荟萃分析。
Ann Intern Med. 2022 Jun;175(6):851-861. doi: 10.7326/M21-4284. Epub 2022 Apr 12.
6
Outcome of Pregnancy in Women With D-Transposition of the Great Arteries: A Systematic Review.D 型大动脉转位女性的妊娠结局：系统评价。
J Am Heart Assoc. 2022 Dec 6;11(23):e026862. doi: 10.1161/JAHA.122.026862. Epub 2022 Nov 29.
7
Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy.沙库巴曲缬沙坦、钠-葡萄糖共转运蛋白 2 抑制剂和维立西呱治疗充血性心力衰竭。
Basic Clin Pharmacol Toxicol. 2022 Apr;130(4):425-438. doi: 10.1111/bcpt.13714. Epub 2022 Feb 17.
8
Late outcome, therapy and systemic ventricular function in patients with a systemic right ventricle: data of the German National Register for Congenital Heart Defects.伴有体循环右心室的患者的远期结果、治疗和系统性心室功能：德国先天性心脏缺陷登记处的数据。
Cardiol Young. 2022 Aug;32(8):1235-1245. doi: 10.1017/S1047951121003954. Epub 2021 Oct 18.
9
Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂和醛固酮拮抗剂联合肾素-血管紧张素系统拮抗剂对 2 型糖尿病合并慢性肾脏病患者主要肾脏不良结局的影响：系统评价和网络荟萃分析。
Diabetes Obes Metab. 2022 Nov;24(11):2159-2168. doi: 10.1111/dom.14801. Epub 2022 Jul 15.
10
A study in ventricular-ventricular interaction. Single right ventricles compared with systemic right ventricles in a dual-chamber circulation.一项关于心室-心室相互作用的研究。在双腔循环中，单右心室与系统性右心室的比较。
Circulation. 1995 Jul 15;92(2):219-30. doi: 10.1161/01.cir.92.2.219.
本文引用的文献
1
Safety and Efficacy of Dapagliflozin in Patients With Systemic Right Ventricular Dysfunction: DAPA-SRV Trial.达格列净治疗系统性右心室功能障碍患者的安全性和有效性：DAPA-SRV试验
J Am Heart Assoc. 2025 Jun 3;14(11):e040302. doi: 10.1161/JAHA.124.040302. Epub 2025 May 29.
2
A Systematic Review and Meta-Analysis of the Safety and Efficacy of SGLT2 Inhibitors in Chronic Heart Failure in ACHD Patients.SGLT2抑制剂在先天性心脏病（ACHD）患者慢性心力衰竭中的安全性和有效性的系统评价与荟萃分析
Am J Cardiovasc Drugs. 2025 Mar;25(2):231-240. doi: 10.1007/s40256-024-00697-7. Epub 2024 Dec 2.
3
Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease.钠-葡萄糖共转运蛋白 2 抑制剂对先天性心脏病成人的影响。
J Am Coll Cardiol. 2024 Apr 16;83(15):1403-1414. doi: 10.1016/j.jacc.2024.02.017. Epub 2024 Mar 25.
4
Dapagliflozin in Patients With a Failing Systemic Right Ventricle: Results From the DAPA-SERVE Trial.达格列净用于右心室功能不全患者：DAPA-SERVE试验结果
JACC Heart Fail. 2024 Apr;12(4):789-791. doi: 10.1016/j.jchf.2024.01.006. Epub 2024 Feb 28.
5
Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF.达格列净对射血分数保留的心力衰竭患者 6 分钟步行距离的影响：PRESERVED-HF 研究。
Circ Heart Fail. 2023 Nov;16(11):e010633. doi: 10.1161/CIRCHEARTFAILURE.123.010633. Epub 2023 Oct 23.
6
End-stage heart failure in congenitally corrected transposition of the great arteries: a multicentre study.先天性矫正型大动脉转位的终末期心力衰竭：一项多中心研究。
Eur Heart J. 2023 Sep 7;44(34):3278-3291. doi: 10.1093/eurheartj/ehad511.
7
The potential of sodium-glucose cotransporter 2 inhibitors for the treatment of systemic right ventricular failure in adults with congenital heart disease.钠-葡萄糖协同转运蛋白2抑制剂治疗先天性心脏病成年患者体循环右心室衰竭的潜力。
Front Cardiovasc Med. 2023 Jun 26;10:1093201. doi: 10.3389/fcvm.2023.1093201. eCollection 2023.
8
Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.达格列净对射血分数保留或轻度降低患者健康状况的影响。
J Am Coll Cardiol. 2023 Feb 7;81(5):460-473. doi: 10.1016/j.jacc.2022.11.006. Epub 2022 Dec 14.
9
Safety and Efficacy of Sacubitril/Valsartan in Patients With a Failing Systemic Right Ventricle: A Prospective Single-Center Study.沙库巴曲缬沙坦治疗右心室功能衰竭患者的安全性和有效性：一项前瞻性单中心研究
Circ Heart Fail. 2023 Feb;16(2):e009848. doi: 10.1161/CIRCHEARTFAILURE.122.009848. Epub 2022 Dec 2.
10
Long-Term Outcomes After Atrial Switch Operation for Transposition of the Great Arteries.大动脉转位的心房调转术后的长期结果。
J Am Coll Cardiol. 2022 Sep 6;80(10):951-963. doi: 10.1016/j.jacc.2022.06.020.
Zotero 插件